<p>法国巴黎银行金融市场在最近向证券交易委员会（SEC）提交的 13F 表格中披露，在第四季度将其在 Travere Therapeutics, Inc.（NASDAQ:TVTX - 免费报告）的持股比例提高了 17.7%。该机构投资者在此期间额外购买了 100,198 股后，持有该公司 665,795 股股票。到最近一个季度末，法国巴黎银行金融市场持有的 Travere Therapeutics 股份占 0.74%，价值为 25,440,000 美元。</p>
<p>获取 <strong>Travere Therapeutics</strong> 的提醒：</p>
<ul>
<li>3 家不为人知的医疗公司</li>
</ul>
<p>其他对冲基金最近也增加或减少了在该公司的持股。Raymond James Financial Inc. 在第二季度新购入了价值 33,000 美元的 Travere Therapeutics 股份。Torren Management LLC 在第四季度新购入了价值 38,000 美元的 Travere Therapeutics 股份。Comerica Bank 在第四季度将其在 Travere Therapeutics 的持股提高了 77.5%。Comerica Bank 现在持有该公司 1,127 股股票，价值 43,000 美元，此前在此期间又购买了 492 股。Garner Asset Management Corp 在第四季度新购入了价值 69,000 美元的 Travere Therapeutics 股份。最后，Headlands Technologies LLC 在第二季度新购入了价值 73,000 美元的 Travere Therapeutics 股份。</p>
<h2>Travere Therapeutics 的内部交易</h2>
<p>在其他消息中，首席会计官 Sandra Calvin 于 4 月 14 日（星期二）出售了 21,977 股该公司的股票。股票以平均价格 41.07 美元出售，总价值为 902,595.39 美元。出售完成后，首席会计官直接持有 42,353 股该公司的股票，估值约为 1,739,437.71 美元。此次交易代表其持股减少了 34.16%。该交易已在向 SEC 提交的文件中披露，文件可通过 SEC 网站访问。该交易是在预先安排的 10b5-1 交易计划下执行的。此外，董事 Roy D. Baynes 于 4 月 14 日（星期二）出售了 32,750 股该公司的股票。股票以平均价格 41.29 美元出售，总交易额为 1,352,247.50 美元。出售后，该董事直接持有 37,500 股公司股票，估值为 1,548,375 美元。此次交易代表其持股减少了 46.62%。该出售的披露信息可在 SEC 的文件中找到。该交易是在预先安排的 10b5-1 交易计划下执行的。在过去的九十天里，内部人士已出售了价值 15,895,428 美元的 400,015 股公司股票。公司内部人士持有公司股票的 4.44%。</p>
<h2>华尔街分析师预测增长</h2>
<ul>
<li>Travere Therapeutics 在鼓舞人心的数据后仍在上升</li>
</ul>
<p>TVTX 最近成为几份分析师报告的主题。HC Wainwright 在周二的报告中将 Travere Therapeutics 的目标价格从 57.00 美元上调至 67.00 美元，并给予该公司 “买入” 评级。Guggenheim 在 4 月 24 日（星期五）的报告中将 Travere Therapeutics 的目标价格从 54.00 美元上调至 56.00 美元，并给予该公司 “买入” 评级。Wedbush 在周三重申了 “跑赢大盘” 评级，并对 Travere Therapeutics 的股票设定了 55.00 美元的目标价格。Wall Street Zen 在 5 月 9 日（星期六）的报告中将 Travere Therapeutics 的评级从 “买入” 下调至 “持有”。最后，花旗集团在周三将 Travere Therapeutics 的目标价格从 59.00 美元上调至 62.00 美元，并给予该公司 “买入” 评级。十位分析师对该股票给予了买入评级，两位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，Travere Therapeutics 目前的共识评级为 “适度买入”，共识目标价格为 48.92 美元。</p>
<p><strong>查看我们最新的 Travere Therapeutics 股票报告</strong></p>
<h2>Travere Therapeutics 股票上涨 2.2%</h2>
<p>周五，TVTX 股票开盘价为 46.18 美元。Travere Therapeutics, Inc.的 52 周低点为 13.88 美元，52 周高点为 48.61 美元。该公司的债务与股本比率为 3.16，速动比率为 3.08，流动比率为 3.13。该公司的 50 日简单移动平均为 39.35 美元，200 日简单移动平均为 34.71 美元。该公司的市值为 42.9 亿美元，市盈率为-200.77，贝塔值为 1.13。</p>
<p>Travere Therapeutics（NASDAQ:TVTX - 获取免费报告）最近于 5 月 4 日（星期一）发布了其财报。该公司报告本季度每股收益为 0.05 美元，超出分析师共识预期的-0.24 美元，超出幅度为 0.29 美元。Travere Therapeutics 的净利润率为-4.00%，股本回报率为-26.16%。该公司在本季度的收入为 1.272 亿美元，而共识预期为 1.3623 亿美元。在去年同期，该公司每股收益为-0.47 美元。与去年同期相比，该公司的收入增长了 55.6%。研究分析师预计 Travere Therapeutics, Inc.将在本财年发布-0.26 美元的每股收益。</p>
<h2>Travere Therapeutics 公司简介</h2>
<p>（免费报告）</p>
<p>Travere Therapeutics, Inc.（NASDAQ: TVTX）是一家总部位于加利福尼亚州圣地亚哥的生物制药公司，致力于开发和商业化针对罕见肾脏和遗传疾病的疗法。公司的使命是通过关注影响小患者群体的疾病，解决治疗选择有限的疾病的未满足需求。Travere 结合了研究、开发和商业能力，将创新药物推向市场。</p>
<p>该公司的主要产品是 sparsentan，一种双重内皮素 - 血管紧张素受体拮抗剂，已获得美国的加速批准。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票，胜过 Travere Therapeutics</li>
<li>大规模 AI 服务器轮换使惠普企业和超微计算机成为焦点</li>
<li>Generac 的 AI 动力转型引发了关于数据中心需求的更大问题</li>
<li>美敦力触底，健康反弹在前</li>
<li>GitLab 的价格恢复获得 traction——是时候上车了吗？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFZUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFZUWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Travere Therapeutics 吗？</h2>
<p>在考虑 Travere Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前... 而 Travere Therapeutics 并不在名单上。</p>
<p>虽然 Travere Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

TVTX

<p>法国外贸银行金融市场在第四季度将其在 Travere Therapeutics 的股份增加了 17.7%，达到 2544 万美元。其他机构如 Comerica Bank 也增加了持股，而内部人士则根据 10b5-1 规则出售了股份。尽管最近的收益超出预期，分析师们普遍维持 “适度买入” 的共识，平均目标价格为 48.92 美元</p>

<p>BNP Paribas Financial Markets raised its stake in Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 17.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 665,795 shares of the company's stock after buying an additional 100,198 shares during the period. BNP Paribas Financial Markets owned 0.74% of Travere Therapeutics worth $25,440,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>法国巴黎银行金融市场在最近向证券交易委员会（SEC）提交的 13F 表格中披露，在第四季度将其在 Travere Therapeutics, Inc.（NASDAQ:TVTX - 免费报告）的持股比例提高了 17.7%。该机构投资者在此期间额外购买了 100,198 股后，持有该公司 665,795 股股票。到最近一个季度末，法国巴黎银行金融市场持有的 Travere Therapeutics 股份占 0.74%，价值为 25,440,000 美元。</p>
</div><p>Get <strong>Travere Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Travere Therapeutics</strong> 的提醒：</p>
</div><ul>
<li>3 Under-the-Radar Healthcare Companies</li>
</ul>
<div class="lb-trans"><ul>
<li>3 家不为人知的医疗公司</li>
</ul>
</div><p>Other hedge funds have also recently added to or reduced their stakes in the company. Raymond James Financial Inc. acquired a new position in shares of Travere Therapeutics during the second quarter worth $33,000. Torren Management LLC acquired a new position in shares of Travere Therapeutics during the fourth quarter worth $38,000. Comerica Bank lifted its holdings in shares of Travere Therapeutics by 77.5% during the fourth quarter. Comerica Bank now owns 1,127 shares of the company's stock worth $43,000 after purchasing an additional 492 shares during the period. Garner Asset Management Corp acquired a new position in shares of Travere Therapeutics during the fourth quarter worth $69,000. Finally, Headlands Technologies LLC acquired a new position in shares of Travere Therapeutics during the second quarter worth $73,000.</p>
<div class="lb-trans"><p>其他对冲基金最近也增加或减少了在该公司的持股。Raymond James Financial Inc. 在第二季度新购入了价值 33,000 美元的 Travere Therapeutics 股份。Torren Management LLC 在第四季度新购入了价值 38,000 美元的 Travere Therapeutics 股份。Comerica Bank 在第四季度将其在 Travere Therapeutics 的持股提高了 77.5%。Comerica Bank 现在持有该公司 1,127 股股票，价值 43,000 美元，此前在此期间又购买了 492 股。Garner Asset Management Corp 在第四季度新购入了价值 69,000 美元的 Travere Therapeutics 股份。最后，Headlands Technologies LLC 在第二季度新购入了价值 73,000 美元的 Travere Therapeutics 股份。</p>
</div><h2>Insider Transactions at Travere Therapeutics</h2>
<div class="lb-trans"><h2>Travere Therapeutics 的内部交易</h2>
</div><p>In other news, CAO Sandra Calvin sold 21,977 shares of the firm's stock in a transaction dated Tuesday, April 14th. The shares were sold at an average price of $41.07, for a total value of $902,595.39. Following the completion of the sale, the chief accounting officer directly owned 42,353 shares of the company's stock, valued at approximately $1,739,437.71. This trade represents a 34.16% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Roy D. Baynes sold 32,750 shares of the business's stock in a transaction dated Tuesday, April 14th. The stock was sold at an average price of $41.29, for a total transaction of $1,352,247.50. Following the sale, the director directly owned 37,500 shares in the company, valued at $1,548,375. The trade was a 46.62% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 400,015 shares of company stock worth $15,895,428. Company insiders own 4.44% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，首席会计官 Sandra Calvin 于 4 月 14 日（星期二）出售了 21,977 股该公司的股票。股票以平均价格 41.07 美元出售，总价值为 902,595.39 美元。出售完成后，首席会计官直接持有 42,353 股该公司的股票，估值约为 1,739,437.71 美元。此次交易代表其持股减少了 34.16%。该交易已在向 SEC 提交的文件中披露，文件可通过 SEC 网站访问。该交易是在预先安排的 10b5-1 交易计划下执行的。此外，董事 Roy D. Baynes 于 4 月 14 日（星期二）出售了 32,750 股该公司的股票。股票以平均价格 41.29 美元出售，总交易额为 1,352,247.50 美元。出售后，该董事直接持有 37,500 股公司股票，估值为 1,548,375 美元。此次交易代表其持股减少了 46.62%。该出售的披露信息可在 SEC 的文件中找到。该交易是在预先安排的 10b5-1 交易计划下执行的。在过去的九十天里，内部人士已出售了价值 15,895,428 美元的 400,015 股公司股票。公司内部人士持有公司股票的 4.44%。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><ul>
<li>Travere Therapeutics Still On The Rise After Encouraging Data</li>
</ul>
<div class="lb-trans"><ul>
<li>Travere Therapeutics 在鼓舞人心的数据后仍在上升</li>
</ul>
</div><p>TVTX has been the topic of several recent analyst reports. HC Wainwright boosted their target price on shares of Travere Therapeutics from $57.00 to $67.00 and gave the company a &#34;buy&#34; rating in a report on Tuesday. Guggenheim boosted their target price on shares of Travere Therapeutics from $54.00 to $56.00 and gave the company a &#34;buy&#34; rating in a report on Friday, April 24th. Wedbush restated an &#34;outperform&#34; rating and issued a $55.00 target price on shares of Travere Therapeutics in a report on Wednesday. Wall Street Zen lowered shares of Travere Therapeutics from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Saturday, May 9th. Finally, Citigroup boosted their target price on shares of Travere Therapeutics from $59.00 to $62.00 and gave the company a &#34;buy&#34; rating in a report on Wednesday. Ten analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Travere Therapeutics presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $48.92.</p>
<div class="lb-trans"><p>TVTX 最近成为几份分析师报告的主题。HC Wainwright 在周二的报告中将 Travere Therapeutics 的目标价格从 57.00 美元上调至 67.00 美元，并给予该公司 “买入” 评级。Guggenheim 在 4 月 24 日（星期五）的报告中将 Travere Therapeutics 的目标价格从 54.00 美元上调至 56.00 美元，并给予该公司 “买入” 评级。Wedbush 在周三重申了 “跑赢大盘” 评级，并对 Travere Therapeutics 的股票设定了 55.00 美元的目标价格。Wall Street Zen 在 5 月 9 日（星期六）的报告中将 Travere Therapeutics 的评级从 “买入” 下调至 “持有”。最后，花旗集团在周三将 Travere Therapeutics 的目标价格从 59.00 美元上调至 62.00 美元，并给予该公司 “买入” 评级。十位分析师对该股票给予了买入评级，两位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，Travere Therapeutics 目前的共识评级为 “适度买入”，共识目标价格为 48.92 美元。</p>
</div><p><strong>View Our Latest Stock Report on Travere Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 Travere Therapeutics 股票报告</strong></p>
</div><h2>Travere Therapeutics Trading Up 2.2%</h2>
<div class="lb-trans"><h2>Travere Therapeutics 股票上涨 2.2%</h2>
</div><p>Shares of TVTX stock opened at $46.18 on Friday. Travere Therapeutics, Inc. has a 52-week low of $13.88 and a 52-week high of $48.61. The company has a debt-to-equity ratio of 3.16, a quick ratio of 3.08 and a current ratio of 3.13. The company has a 50-day simple moving average of $39.35 and a two-hundred day simple moving average of $34.71. The company has a market capitalization of $4.29 billion, a price-to-earnings ratio of -200.77 and a beta of 1.13.</p>
<div class="lb-trans"><p>周五，TVTX 股票开盘价为 46.18 美元。Travere Therapeutics, Inc.的 52 周低点为 13.88 美元，52 周高点为 48.61 美元。该公司的债务与股本比率为 3.16，速动比率为 3.08，流动比率为 3.13。该公司的 50 日简单移动平均为 39.35 美元，200 日简单移动平均为 34.71 美元。该公司的市值为 42.9 亿美元，市盈率为-200.77，贝塔值为 1.13。</p>
</div><p>Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last released its earnings results on Monday, May 4th. The company reported $0.05 earnings per share for the quarter, beating analysts' consensus estimates of ($0.24) by $0.29. Travere Therapeutics had a negative net margin of 4.00% and a negative return on equity of 26.16%. The firm had revenue of $127.20 million during the quarter, compared to the consensus estimate of $136.23 million. During the same period in the prior year, the firm earned ($0.47) EPS. The company's revenue was up 55.6% compared to the same quarter last year. Research analysts anticipate that Travere Therapeutics, Inc. will post -0.26 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Travere Therapeutics（NASDAQ:TVTX - 获取免费报告）最近于 5 月 4 日（星期一）发布了其财报。该公司报告本季度每股收益为 0.05 美元，超出分析师共识预期的-0.24 美元，超出幅度为 0.29 美元。Travere Therapeutics 的净利润率为-4.00%，股本回报率为-26.16%。该公司在本季度的收入为 1.272 亿美元，而共识预期为 1.3623 亿美元。在去年同期，该公司每股收益为-0.47 美元。与去年同期相比，该公司的收入增长了 55.6%。研究分析师预计 Travere Therapeutics, Inc.将在本财年发布-0.26 美元的每股收益。</p>
</div><h2>Travere Therapeutics Profile</h2>
<div class="lb-trans"><h2>Travere Therapeutics 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Travere Therapeutics, Inc NASDAQ: TVTX is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company's mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.</p>
<div class="lb-trans"><p>Travere Therapeutics, Inc.（NASDAQ: TVTX）是一家总部位于加利福尼亚州圣地亚哥的生物制药公司，致力于开发和商业化针对罕见肾脏和遗传疾病的疗法。公司的使命是通过关注影响小患者群体的疾病，解决治疗选择有限的疾病的未满足需求。Travere 结合了研究、开发和商业能力，将创新药物推向市场。</p>
</div><p>The company's lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.</p>
<div class="lb-trans"><p>该公司的主要产品是 sparsentan，一种双重内皮素 - 血管紧张素受体拮抗剂，已获得美国的加速批准。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Travere Therapeutics</li>
<li>The Great AI Server Rotation Puts Hewlett Packard Enterprise and Super Micro Computer in Focus</li>
<li>Generac’s AI Power Pivot Raises a Bigger Question About Data Center Demand</li>
<li>Medtronic Bottoms, Healthy Rebound Ahead</li>
<li>GitLab’s Price Recovery Gains Traction—Time to Get On Board?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Travere Therapeutics</li>
<li>大规模 AI 服务器轮换使惠普企业和超微计算机成为焦点</li>
<li>Generac 的 AI 动力转型引发了关于数据中心需求的更大问题</li>
<li>美敦力触底，健康反弹在前</li>
<li>GitLab 的价格恢复获得 traction——是时候上车了吗？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFZUWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=TVTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Travere Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Travere Therapeutics 吗？</h2>
</div><p>Before you consider Travere Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Travere Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Travere Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前... 而 Travere Therapeutics 并不在名单上。</p>
</div><p>While Travere Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Travere Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

BNP Paribas Financial Markets Has $25.44 Million Stock Position in Travere Therapeutics, Inc. $TVTX

Market Beat

Travere Therapeutics

法国巴黎银行(ADR)

瑞杰金融

Comerica

花旗

RAYMOND JAMES FINANCIAL INC 6.375%DEP SHS REP 1/40TH FXD FLTG SER B

COMERICA INC 6.875 % DEP PFD SER B

CITIGROUP INC 6.250 NON CUM SER II PFD WI

法国巴黎银行金融市场在 Travere Therapeutics, Inc. $TVTX 持有价值 2544 万美元的股票头寸